AUTHORS
Qian Sun, MD, Hongrui Zhang, MD2, Wenjie Liu, MD3, Yu Zhu, MD4, Sixuan Qian5, Jianyong Li, MD6, Lei Fan, MD7, Ming Hong, MD8
AFFILIATIONS
1 The First Affiliated Hospital with Nanjing Medical University, Jiangsu Province Hospital, Nanjing, Jiangsu Province, China
2 The First Affiliated Hospital with Nanjing Medical University, Jiangsu Province Hospital, Nanjing, Jiangsu Province, China
3 The First Affiliated Hospital with Nanjing Medical University, Jiangsu Province Hospital, Nanjing, Jiangsu Province, China
4 The First Affiliated Hospital with Nanjing Medical University, Jiangsu Province Hospital, Nanjing, Jiangsu Province, China
5 The First Affiliated Hospital with Nanjing Medical University, Jiangsu Province Hospital, Nanjing, Jiangsu Province, China
6 The First Affiliated Hospital with Nanjing Medical University, Jiangsu Province Hospital, Nanjing, Jiangsu Province, China
7 The First Affiliated Hospital with Nanjing Medical University, Jiangsu Province Hospital, Nanjing, Jiangsu Province, China
8 The First Affiliated Hospital with Nanjing Medical University, Jiangsu Province Hospital, Nanjing, Jiangsu Province, China
ABSTRACT
Background: Patients with relapsed/refractory acute myeloid leukemia (R/R AML) have a dismal prognosis; salvage chemotherapy yields complete remission (CR) rates of 20%-40%, and median overall survival (OS) is often <6 months. Aclarubicin exerts antileukemic activity via chromatin damage with markedly lower cardiotoxicity than conventional anthracyclines. Combining aclarubicin with the BCL-2 inhibitor venetoclax and a hypomethylating agent (HMA) may enhance efficacy while reducing toxicity. This study evaluated the efficacy and safety of venetoclax plus decitabine/azacitidine and aclarubicin (VAA) in R/R AML.
Methods: This prospective, multicenter, single-arm phase II trial (ChiCTR2400088404) planned to enroll 28 patients; 27 were actually enrolled (WHO 2016 R/R AML, age≥18 years, ECOG 0-2). The VAA regimen: venetoclax 100 mg d1, 200 mg d2, 400 mg d3-21 orally; decitabine 20 mg/m2/d d1-5 or azacitidine 75 mg/m2/d d1-7 (per patient preference); aclarubicin 10 mg/m2/d d1-4. Response was assessed after one cycle. Patients achieving composite CR (CRc=CR+CRi) proceeded to allo-HSCT if a donor was available; others continued VAA or cytarabine-based consolidation, followed by mutation-targeted maintenance. The primary endpoint was CRc rate after one cycle. Secondary endpoints: partial response (PR) rate, overall response rate (ORR), measurable residual disease (MRD) negativity, OS, disease-free survival (DFS), and adverse events (AEs).
Results: Median age was 56 (18-75) years; 19 (70.4%) were male; 16 (59.3%) had refractory disease. ELN 2022 risk: favorable 2 (7.4%), intermediate 5 (18.5%), adverse 20 (74.1%). KMT2A rearrangements were present in 2, FLT3-ITD in 6 (22.2%), TP53 mutations in 6 (22.2%). After one cycle, CRc rate was 51.9% (14/27), PR rate 14.8%, ORR 66.7%. Among CRc patients, 71.4% (10/14) achieved MRD negativity. With a median follow-up of 13.3 months, median OS was 4.9 months; 6-month, 1-year, and 2-year OS rates were 42.8%, 33.3%, and 33.3%. Median DFS was 6.1 months, with 6-month, 1-year, and 2-year DFS rates of 50.4%, 42.0%, and 42.0%. Grade ≥3 AEs were predominantly hematologic: neutropenia 81.5%, anemia 70.4%, thrombocytopenia 85.2%, febrile neutropenia 48.1%, pneumonia 29.6%. Non-hematologic toxicities were mild.
Conclusions: In this heavily adverse-risk R/R AML cohort (74.1% adverse-risk, 22.2% TP53-mutated), the VAA regimen produced a CRc rate of 51.9%, MRD negativity of 71.4%, and durable 1-/2-year OS of 33.3%. Adding aclarubicin to the venetoclax-HMA backbone exploits its unique chromatin-damaging mechanism (nucleosome disassembly and histone eviction independent of DNA double-strand breaks) with minimal cardiotoxicity and secondary malignancy risk, favoring elderly or cardiac-compromised patients. Grade 3-4 cytopenias were common but manageable, and the regimen effectively bridged to allo-HSCT, offering long-term survival potential. Limitations include the single-arm design, small sample size, and limited follow-up; randomized studies are warranted. VAA is an effective, low-toxicity salvage strategy for R/R AML with promising clinical applicability.
DISCLOSURES
Wenjie Liu, MD: No relevant conflicts of interest to declare.